0001104659-24-001157.txt : 20240104 0001104659-24-001157.hdr.sgml : 20240104 20240104082204 ACCESSION NUMBER: 0001104659-24-001157 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240104 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: First Wave BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 24509815 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 8-K 1 tm241946d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 4, 2024

	First Wave BioPharma, Inc.
	(Exact name of registrant as specified in its charter)

Delaware		001-37853		46-4993860
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

777 Yamato Road, Suite 502

Boca Raton, Florida

33431

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (561) 589-7020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		FWBI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

On January 4, 2024, the Company released a letter from James Sapirstein, the Company’s Chief Executive Officer, to its shareholders. A copy of the letter is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing or document, except as shall be expressly set forth by specific reference in such a filing or document.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

The following Exhibits are being furnished with this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Press Release, dated January 4, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	First Wave BioPharma, Inc.

January 4, 2024	By:	/s/ James Sapirstein
	Name:	James Sapirstein
	Title:	Chief Executive Officer

EX-99.1 2 tm241946d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

Multiple clinical and development milestones anticipated in 2024, including initiation of Phase 3 clinical trial investigating latiglutenase in celiac disease in the event the company closes its potential merger transaction with ImmunogenX

BOCA RATON, FL., January 4, 2024 – First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, has issued a Letter to Stockholders highlighting the Company’s recent accomplishments and plans for 2024. The full text of the letter follows.

A MESSAGE FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER

To my fellow stockholders,

Strong Strategic Rationale and Operational Fit for Anticipated Business Combination with ImmunogenX

The close of 2023 has been an exciting period for First Wave BioPharma, highlighted by the recently announced potential business combination with ImmunogenX. We recently announced a non-binding term sheet with ImmunogenX and are currently in negotiations for a definitive agreement. In the event this potential transaction is completed, we will gain access to Phase 3-ready latiglutenase, a potentially first-in-class, targeted, oral biotherapeutic for celiac disease, and a team of visionary scientists led by Jack Syage, Ph.D., who is expected to become our President and Chief Operating Officer, and Professor Chaitan Khosla, who completed the seminal work leading to the discovery of latiglutenase at Stanford University.

Any definitive agreement with respect to the potential transaction and completion of the transaction would be subject to approval by the respective parties to that definitive agreement, including approval by our board of directors and/or stockholders, approval by ImmunogenX’s stockholders, various regulatory approvals, and the combined company having sufficient capital to carry out the planned businesses.

Concurrent Strategic Pharma Commercial Agreement and Institutional Investment Anticipated in 1H’24

Additionally, in the event the Company closes the potential ImmunogenX transaction, we would expect to concurrently announce a significant non-dilutive financial investment from a strategic global pharmaceutical company for commercial rights to latiglutenase in the United States and Canada, as well as financing commitments from several institutional investors to fund the drug’s development. These expected investments are based on the potential of latiglutenase to be a first-to-market treatment for celiac disease, a GI-disorder that impacts approximately three million people in the U.S. and for which no approved pharmacologic treatment currently exists.

Latiglutenase: A Phase 3 Ready Asset for Celiac Disease Addressing a Major Unmet Clinical Need

The Phase 3 clinical development plan for latiglutenase has been reviewed by the GI Division of the U.S. Food and Drug Administration (FDA), with initiation of the Phase 3 trials expected in the second half of 2024. This timing could enable latiglutenase to enter the multibillion-dollar celiac disease market by 2027.

In the event the Company closes the potential transaction with ImmunogenX, First Wave BioPharma could become a Phase 3 company with a drug technology that, upon successful completion of the trials and approval by the FDA, could be first-to-market for a GI disease that impacts millions of people and where no approved therapy exists.

We believe this possibility, on its own, offers the potential to substantially enhance the value of First Wave BioPharma for our stockholders given the numerous development and regulatory milestones expected with the latiglutenase program in 2024 and beyond, in the event the Company closes the potential transaction with ImmunogenX. But it is not the only substantial growth opportunity for our company.

Capeserod: A Phase 2 Asset Licensed from Sanofi with Applications in Multi-Billion Dollar GI Indications

Prior to our discussions with ImmunogenX, we strengthened our GI-focused pipeline with the addition of capeserod, a selective 5-HT4 receptor partial agonist, from Sanofi. Artificial intelligence (AI)-empowered analyses indicate the drug’s prokinetic mechanism of action has potential applications for several gastrointestinal disorders in multibillion-dollar markets, such as gastroparesis, where there are significant unmet clinical needs and no commercially available therapies without serious side effects. Based on these analyses and buoyed by capeserod’s strong safety profile, we are moving rapidly to initiate Phase 2 clinical trials in 2024 and will be liaising with the FDA to establish the best developmental and regulatory pathway forward.

Niclosamide: Streamlining Our Clinical Pipeline

In late December, we announced the signing of a non-binding term sheet to sell our niclosamide inflammatory bowel disease (IBD) program to an undisclosed biopharmaceutical company. The non-binding term sheet includes a low seven-figure payment to First Wave BioPharma along with economics related to future milestones and royalties.

We believe niclosamide has potential as a non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate IBDs. However, we made the strategic decision to streamline our development pipeline following the in-licensing of Phase 2-ready capeserod from Sanofi and the pending addition of Phase 3-ready latiglutenase. If completed, we believe this transaction would allow us to focus our development efforts on those assets, while providing the potential to infuse our company with additional, non-dilutive capital.

First Wave BioPharma: A Diversified Late-Stage Clinical Portfolio with Three GI Assets

In the event the Company closes the potential transaction with ImmunogenX, latiglutenase and capeserod will headline a late-stage GI pipeline that is unrivaled by other companies of similar size to First Wave. Add to that, ongoing analyses of the adrulipase Phase 2 data have been promising and suggest potential opportunities to advance the program. We plan to request a meeting with the FDA in Q1’2024 to discuss the data and a clinical development plan given the shortcomings with current treatments for exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

For our stockholders…

This is a very exciting time in the growth and evolution of First Wave BioPharma, and we are working diligently to advance our multiple, late-stage development programs to bring relief to patients living daily with the often painful, dangerous and discomforting symptoms inherent to gastrointestinal disease.

2024 has the potential to be a year of significant growth for First Wave BioPharma, and once again, I thank all of our stockholders for your continued support.

Sincerely,

James Sapirstein

Chairman and CEO

First Wave BioPharma, Inc.

About First Wave BioPharma, Inc.

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies – capeserod, a selective 5-HT4 receptor partial agonist which First Wave will develop for gastrointestinal (GI) indications; the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether the sale of niclosamide, the potential transaction with ImmunogenX and any concurrent financing or licensing transaction, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the Company will be able to realize the benefits of the proposed transactions described herein; the Company’s ability to integrate the assets and commercial operations contemplated to be acquired from ImmunogenX into the Company’s business; whether the closing conditions can be met or the definitive agreements can be executed for the sale of niclosamide, the transaction with ImmunogenX, any concurrent financing or licensing transaction, or any other contemplated transaction, whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with Nasdaq’s continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

First Wave BioPharma, Inc.

777 Yamato Road, Suite 502

Boca Raton, FL 33431

Phone: (561) 589-7020

info@firstwavebio.com

Media contact:

Tiberend Strategic Advisors, Inc.

David Schemelia

(609) 468-9325

dschemelia@tiberend.com

EX-101.SCH 3 fwbi-20240104.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fwbi-20240104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fwbi-20240104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 04, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 04, 2024
Entity File Number	001-37853
Entity Registrant Name	First Wave BioPharma, Inc.
Entity Central Index Key	0001604191
Entity Tax Identification Number	46-4993860
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	777 Yamato Road
Entity Address, Address Line Two	Suite 502
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	589-7020
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	FWBI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm241946d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001604191 2024-01-04 2024-01-04 iso4217:USD shares iso4217:USD shares false 0001604191 8-K 2024-01-04 First Wave BioPharma, Inc. DE 001-37853 46-4993860 777 Yamato Road Suite 502 Boca Raton FL 33431 561 589-7020 false false false false Common Stock, par value $0.0001 per share FWBI NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://firstwavebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports fwbi-20240104.xsd fwbi-20240104_lab.xml fwbi-20240104_pre.xml tm241946d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm241946d1_8k.htm": { "nsprefix": "FWBI", "nsuri": "http://firstwavebio.com/20240104", "dts": { "schema": { "local": [ "fwbi-20240104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "fwbi-20240104_lab.xml" ] }, "presentationLink": { "local": [ "fwbi-20240104_pre.xml" ] }, "inline": { "local": [ "tm241946d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://firstwavebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm241946d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm241946d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-24-001157-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-001157-xbrl.zip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